The validations confirm the completion of the applications and commence the scientific review process
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Subscribe To Our Newsletter & Stay Updated
